GLP-1 agonists are popular weight loss treatments for overweight individuals, but data shows no medical cost offset. While GLP-1s like Wegovy have cardiovascular benefits, their high cost makes them not cost-effective in the U.S. for now.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay